JP2018509148A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018509148A5 JP2018509148A5 JP2017547087A JP2017547087A JP2018509148A5 JP 2018509148 A5 JP2018509148 A5 JP 2018509148A5 JP 2017547087 A JP2017547087 A JP 2017547087A JP 2017547087 A JP2017547087 A JP 2017547087A JP 2018509148 A5 JP2018509148 A5 JP 2018509148A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- immune cells
- cell
- allogeneic
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 13
- 210000002865 immune cell Anatomy 0.000 claims 10
- 230000000735 allogeneic effect Effects 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 6
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 5
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 claims 5
- 101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 claims 5
- 230000001506 immunosuppresive effect Effects 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 230000002779 inactivation Effects 0.000 claims 4
- 230000003612 virological effect Effects 0.000 claims 4
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000415 inactivating effect Effects 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102100030346 Antigen peptide transporter 1 Human genes 0.000 claims 1
- 102100031780 Endonuclease Human genes 0.000 claims 1
- 108010042407 Endonucleases Proteins 0.000 claims 1
- 101710086766 FP protein Proteins 0.000 claims 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 1
- 101100048372 Human cytomegalovirus (strain AD169) H301 gene Proteins 0.000 claims 1
- 101100048373 Human cytomegalovirus (strain Merlin) UL18 gene Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000043129 MHC class I family Human genes 0.000 claims 1
- 108091054437 MHC class I family Proteins 0.000 claims 1
- 108010023335 Member 2 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 claims 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 101710163270 Nuclease Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- 101150037769 TRX2 gene Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201570138 | 2015-03-11 | ||
| DKPA201570138 | 2015-03-11 | ||
| PCT/EP2016/055332 WO2016142532A1 (en) | 2015-03-11 | 2016-03-11 | Methods for engineering allogeneic t cell to increase their persistence and/or engraftment into patients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018509148A JP2018509148A (ja) | 2018-04-05 |
| JP2018509148A5 true JP2018509148A5 (OSRAM) | 2019-04-11 |
Family
ID=52682595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017547087A Pending JP2018509148A (ja) | 2015-03-11 | 2016-03-11 | 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11186824B2 (OSRAM) |
| EP (1) | EP3268388A1 (OSRAM) |
| JP (1) | JP2018509148A (OSRAM) |
| KR (1) | KR20170137079A (OSRAM) |
| CN (1) | CN107683333A (OSRAM) |
| AU (1) | AU2016231061B2 (OSRAM) |
| BR (1) | BR112017018224A2 (OSRAM) |
| CA (1) | CA2978840A1 (OSRAM) |
| IL (1) | IL253879A0 (OSRAM) |
| MX (1) | MX2017011418A (OSRAM) |
| RU (1) | RU2017134441A (OSRAM) |
| WO (1) | WO2016142532A1 (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102228828B1 (ko) * | 2014-03-11 | 2021-03-16 | 셀렉티스 | 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법 |
| RU2018106515A (ru) | 2015-07-21 | 2019-08-21 | Зе Чилдрен'С Медикал Сентер Корпорейшн | Pd-l1-экспрессирующие гемопоэтические стволовые клетки и применения |
| SG10202109655VA (en) | 2015-12-04 | 2021-10-28 | Novartis Ag | Compositions and methods for immunooncology |
| AU2017330423A1 (en) * | 2016-09-23 | 2019-04-11 | University Of Southern California | Chimeric antigen receptors and compositions and methods of use thereof |
| WO2018115189A1 (en) | 2016-12-21 | 2018-06-28 | Cellectis | Stably enginereed proteasome inhibitor resistant immune cells for immunotherapy |
| EA201991692A1 (ru) * | 2017-01-13 | 2019-12-30 | Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния | Иммуносконструированные плюрипотентные клетки |
| JP2020513832A (ja) | 2017-03-22 | 2020-05-21 | ノバルティス アーゲー | 免疫腫瘍学のための組成物および方法 |
| KR20190141206A (ko) * | 2017-04-19 | 2019-12-23 | 알로젠 테라퓨틱스 인코포레이티드 | 개선된 t 세포 조성물 및 방법 |
| CN107177632B (zh) * | 2017-05-27 | 2020-02-07 | 上海优卡迪生物医药科技有限公司 | 一种基于octs技术的髓系白血病car-t治疗载体及其构建方法和应用 |
| SG10202108528QA (en) | 2017-06-02 | 2021-09-29 | Pfizer | Chimeric antigen receptors targeting flt3 |
| US11879137B2 (en) | 2017-09-22 | 2024-01-23 | The Children's Medical Center Corporation | Treatment of type 1 diabetes and autoimmune diseases or disorders |
| WO2019076486A1 (en) * | 2017-10-19 | 2019-04-25 | Cellectis | TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY |
| CN109836497A (zh) * | 2017-11-25 | 2019-06-04 | 深圳宾德生物技术有限公司 | 一种靶向egfr的单链抗体、嵌合抗原受体t细胞及其制备方法和应用 |
| AU2019216269B2 (en) | 2018-01-30 | 2025-05-01 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen |
| EP3757133A4 (en) * | 2018-02-11 | 2021-12-01 | Jiangsu Hengrui Medicine Co., Ltd. | ISOLATED ANTIGENIC CHEMICAL RECEPTOR, MODIFIED T LYMPHOCYTE INCLUDING IT AND ASSOCIATED USE |
| US20210077530A1 (en) * | 2018-04-26 | 2021-03-18 | Baylor College Of Medicine | Auto/allo-immune defense receptors for the selective targeting of activated pathogenic t cells and nk cells |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| US12454694B2 (en) | 2018-09-07 | 2025-10-28 | Beam Therapeutics Inc. | Compositions and methods for improving base editing |
| CN109055380B (zh) * | 2018-09-19 | 2021-08-27 | 深圳市菲鹏生物治疗股份有限公司 | 一种通用型car-t细胞的制备方法 |
| JP2022511345A (ja) * | 2018-09-21 | 2022-01-31 | カファ セラピューティクス リミテッド | ＣＲＩＳＰＲ／Ｃａｓシステムに基づいた細胞の遺伝子編集の方法 |
| CN109293773B (zh) * | 2018-09-25 | 2020-09-04 | 上海邦耀生物科技有限公司 | 靶向cd38蛋白的抗体、嵌合抗原受体和药物 |
| AU2019372673A1 (en) * | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| EP3877414A1 (en) * | 2018-11-07 | 2021-09-15 | CRISPR Therapeutics AG | Anti-cd33 immune cell cancer therapy |
| KR20210118945A (ko) | 2019-02-15 | 2021-10-01 | 유니버시티 오브 써던 캘리포니아 | Lym-1 및 lym-2 항체 조성물 및 개선된 car 구성물 |
| US20220220561A1 (en) * | 2019-03-18 | 2022-07-14 | Advanced ReGen Medical Technologies, LLC | Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment |
| US12006511B2 (en) | 2019-04-15 | 2024-06-11 | The Medical College Of Wisconsin, Inc. | Recombinant PD-L1 peptides and methods of use |
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| JP2022532174A (ja) | 2019-05-10 | 2022-07-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 修飾多能性細胞 |
| EP3991746A4 (en) * | 2019-06-26 | 2023-08-09 | Takeda Pharmaceutical Company Limited | TRANSFECTION METHOD |
| EP4003375A4 (en) * | 2019-07-31 | 2023-09-06 | Forty Seven, Inc. | DEPLETION DIETS FOR MODIFIED T CELL OR NK CELL THERAPY |
| WO2021119489A1 (en) | 2019-12-11 | 2021-06-17 | A2 Biotherapeutics, Inc. | Lilrb1-based chimeric antigen receptor |
| KR102246067B1 (ko) * | 2020-05-13 | 2021-04-29 | (주)세렌라이프 | 효능이 증진된 줄기세포를 포함하는 세포 생착능 증진용 조성물 |
| CA3185067A1 (en) * | 2020-05-26 | 2021-12-02 | Kouichi Tamura | Hypoimmunogenic cells |
| MX2023002017A (es) | 2020-08-20 | 2023-04-28 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para ceacam. |
| EP4100028A4 (en) | 2020-08-20 | 2023-07-26 | A2 Biotherapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATMENT OF MESOTHELIN-POSITIVE CARCINOMAS |
| ES2984902T3 (es) | 2020-08-20 | 2024-10-31 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para EGFR |
| US20240000938A1 (en) * | 2020-11-24 | 2024-01-04 | A2 Biotherapeutics, Inc. | Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity |
| CN116635064A (zh) | 2020-12-18 | 2023-08-22 | 世纪治疗股份有限公司 | 具有适应性受体特异性的嵌合抗原受体系统 |
| WO2022192895A1 (en) * | 2021-03-10 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions and methods to reduce therapeutic t cell toxicity |
| EP4547825A1 (en) | 2022-07-01 | 2025-05-07 | Novo Nordisk A/S | Enhancing neuronal differentiation of ventral midbrain neural progenitor cells |
| WO2025003393A1 (en) | 2023-06-30 | 2025-01-02 | Novo Nordisk A/S | Enhancing neuronal differentiation of neural progenitor cells |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5574205A (en) * | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US20060222633A1 (en) | 2000-05-11 | 2006-10-05 | Yale University | Prevention, decrease, and/or treatment of immunoreactivity by depleting and/or inactivating antigen presenting cells in the host |
| US7094874B2 (en) * | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| JP4753119B2 (ja) | 2003-03-14 | 2011-08-24 | セレクティス ソシエテ アノニム | 大量処理の生体外エレクトロポレーション法 |
| JP4667451B2 (ja) * | 2004-04-05 | 2011-04-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Ｎｋｇ２ｄの調節 |
| US8986712B2 (en) | 2009-11-29 | 2015-03-24 | Yeda Research And Development Co., Ltd. | Peptides derived from HIV-1 gp41 transmembrane domain for t-immunomodulation |
| IL323000A (en) | 2010-03-05 | 2025-10-01 | Univ Johns Hopkins | Compositions and methods for antibodies and fusion proteins targeted for immune modulation |
| JP5996630B2 (ja) | 2011-04-05 | 2016-09-21 | セレクティスＣｅｌｌｅｃｔｉｓ | コンパクトｔａｌｅ−ヌクレアーゼを作製する方法及びその使用 |
| CA2873402C (en) | 2012-05-15 | 2023-10-24 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN111676196A (zh) * | 2012-05-25 | 2020-09-18 | 塞勒克提斯公司 | 工程化异体和免疫抑制耐受性t细胞的方法 |
| US20150017136A1 (en) | 2013-07-15 | 2015-01-15 | Cellectis | Methods for engineering allogeneic and highly active t cell for immunotherapy |
| DK2893004T3 (en) | 2012-09-04 | 2019-02-04 | Cellectis | MULTI-CHAIN CHEMICAL ANTIGEN RECEPTOR AND APPLICATIONS THEREOF |
| US9902973B2 (en) | 2013-04-11 | 2018-02-27 | Caribou Biosciences, Inc. | Methods of modifying a target nucleic acid with an argonaute |
| AU2014266833B2 (en) | 2013-05-13 | 2020-07-02 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| EP3309248B1 (en) * | 2013-05-29 | 2021-06-09 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| CA2937711C (en) | 2014-02-14 | 2020-10-20 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells |
| MX370272B (es) | 2014-03-19 | 2019-12-09 | Cellectis | Receptores de antigeno quimerico especifico de cd123 para inmunoterapia de cancer. |
-
2016
- 2016-03-11 AU AU2016231061A patent/AU2016231061B2/en active Active
- 2016-03-11 KR KR1020177028154A patent/KR20170137079A/ko not_active Withdrawn
- 2016-03-11 EP EP16710948.7A patent/EP3268388A1/en active Pending
- 2016-03-11 MX MX2017011418A patent/MX2017011418A/es unknown
- 2016-03-11 RU RU2017134441A patent/RU2017134441A/ru not_active Application Discontinuation
- 2016-03-11 BR BR112017018224A patent/BR112017018224A2/pt not_active IP Right Cessation
- 2016-03-11 CN CN201680014457.5A patent/CN107683333A/zh active Pending
- 2016-03-11 WO PCT/EP2016/055332 patent/WO2016142532A1/en not_active Ceased
- 2016-03-11 CA CA2978840A patent/CA2978840A1/en active Pending
- 2016-03-11 JP JP2017547087A patent/JP2018509148A/ja active Pending
- 2016-03-11 US US15/556,558 patent/US11186824B2/en active Active
-
2017
- 2017-08-07 IL IL253879A patent/IL253879A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018509148A5 (OSRAM) | ||
| Haubner et al. | Cooperative CAR targeting to selectively eliminate AML and minimize escape | |
| JP7340638B2 (ja) | Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用 | |
| RU2017134441A (ru) | Способы конструирования аллогенных т-клеток для повышения их персистенции и/или приживления у пациентов | |
| Vella et al. | CD4+ T cell differentiation in chronic viral infections: the Tfh perspective | |
| Starbeck-Miller et al. | Cutting edge: Expression of FcγRIIB tempers memory CD8 T cell function in vivo | |
| Dolcetti et al. | Immunotherapy for gastric cancer: time for a personalized approach? | |
| JP2019528769A5 (OSRAM) | ||
| Escobar et al. | Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens | |
| Kamphorst et al. | CD4 T-cell immunotherapy for chronic viral infections and cancer | |
| WO2018023025A8 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2017535284A5 (OSRAM) | ||
| Zamarin et al. | Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer | |
| JP2019531745A5 (OSRAM) | ||
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| WO2013176916A8 (en) | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells | |
| JP2018529327A5 (OSRAM) | ||
| WO2019232409A9 (en) | Methods for genome editing and activation of cells | |
| CA2924252C (en) | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions | |
| JP2017538401A5 (OSRAM) | ||
| PH12020551124A1 (en) | Bispecific antibody | |
| RU2015155821A (ru) | Вакцины против малярии | |
| JP2015143226A5 (OSRAM) | ||
| JP2018509163A5 (OSRAM) | ||
| JP2017513472A5 (OSRAM) |